GlassScriptPhysician profile
Melanie A Ortleb
NPI 1154611622
$2,088.96
in general payments reported to CMS, 2019-2025
23 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $193 · 2021: $27.00 · 2022: $557 · 2023: $500 · 2024: $344 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $520.55 | 2019-2025 | |
| Janssen Biotech, INC. | $215.87 | 2019-2024 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $188.01 | 2019-2025 | Libtayo, Dupixent |
| Pfizer INC. | $168.99 | 2019-2024 | |
| Leo Pharma INC. | $142.91 | 2022-2025 | Adbry |
| Dermavant Sciences, INC. | $120.71 | 2023-2024 | Vtama |
| Allergan, INC. | $82.25 | 2019-2022 | |
| Incyte Corporation | $72.86 | 2023-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $69.99 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.20 | 2022-2024 | Jublia, Arazlo, Cabtreo |
| Sun Pharmaceutical Industries INC. | $66.94 | 2019-2022 | |
| Almirall LLC | $61.38 | 2024 | Seysara |
| Genzyme Corporation | $58.64 | 2023-2024 | |
| Ucb, INC. | $54.03 | 2020-2024 | Bimzelx |
| Amgen INC. | $46.12 | 2023-2025 | Enbrel, Otezla, Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.82 | 2023 | |
| Lilly USA, LLC | $23.26 | 2019 | |
| Arcutis Biotherapeutics, INC. | $22.43 | 2023 | |
| Biofrontera INC. | $22.12 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Dermira, INC. | $18.83 | 2020 | |
| Celgene Corporation | $14.26 | 2019 | |
| Galderma Laboratories, L.P. | $13.79 | 2020 | |
| Senseonics, Incorporated | $9.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Ortleb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.